A comparison of methotrexate with placebo for the maintenance of remission in Crohn's disease. North American Crohn's Study Group Investigators.

BACKGROUND Patients with Crohn's disease often have relapses. Better treatments are needed for the maintenance of remission. Although methotrexate is an effective short-term treatment for Crohn's disease, its role in maintaining remissions is not known. METHODS We conducted a double-blind, placebo-controlled, multicenter study of patients with chronically active Crohn's disease who had entered remission after 16 to 24 weeks of treatment with 25 mg of methotrexate given intramuscularly once weekly. Patients were randomly assigned to receive either methotrexate at a dose of 15 mg intramuscularly once weekly or placebo for 40 weeks. No other treatments for Crohn's disease were permitted. We compared the efficacy of treatment by analyzing the proportion of patients who remained in remission at week 40. Remission was defined as a score of 150 or less on the Crohn's Disease Activity Index. RESULTS Forty patients received methotrexate, and 36 received placebo. At week 40, 26 patients (65 percent) were in remission in the methotrexate group, as compared with 14 (39 percent) in the placebo group (P=0.04; absolute reduction in the risk of relapse, 26.1 percent; 95 percent confidence interval, 4.4 percent to 47.8 percent). Fewer patients in the methotrexate group than in the placebo group required prednisone for relapse (11 of 40 [28 percent] vs. 21 of 36 [58 percent], P=0.01). None of the patients who received methotrexate had a severe adverse event; one patient in this group withdrew because of nausea. CONCLUSIONS In patients with Crohn's disease who enter remission after treatment with methotrexate, a low dose of methotrexate maintains remission.

[1]  D. Sherry,et al.  Current treatment by United States and Canadian pediatric rheumatologists. , 1999, The Journal of rheumatology.

[2]  M. Ward.  Trends in the use of disease modifying antirheumatic medications in rheumatoid arthritis, 1980-1995: results from the National Ambulatory Medical Care Surveys. , 1999, The Journal of rheumatology.

[3]  P. Tugwell,et al.  How Canadian and US rheumatologists treat moderate or aggressive rheumatoid arthritis: a survey. , 1998, The Journal of rheumatology.

[4]  E. Bawle,et al.  Adult and two children with fetal methotrexate syndrome. , 1998, Teratology.

[5]  J. Kremer,et al.  Clinical, laboratory, radiographic, and histopathologic features of methotrexate-associated lung injury in patients with rheumatoid arthritis: a multicenter study with literature review. , 1997, Arthritis and rheumatism.

[6]  R. Rau,et al.  Long-term treatment of destructive rheumatoid arthritis with methotrexate. , 1997, The Journal of rheumatology.

[7]  A. Clegg,et al.  A case-control study of measles vaccination and inflammatory bowel disease , 1997, The Lancet.

[8]  M. Weinblatt,et al.  Histologic liver abnormalities in an autopsy series of patients with rheumatoid arthritis. , 1997, British journal of rheumatology.

[9]  A. Forbes,et al.  Absence of skin sensitivity to oxides of aluminium, silicon, titanium or zirconium in patients with Crohn's disease. , 1996, Gut.

[10]  D. Jewell,et al.  Budesonide prolongs time to relapse in ileal and ileocaecal Crohn's disease. A placebo controlled one year study. , 1996, Gut.

[11]  J. Kremer,et al.  Significant changes in serum AST across hepatic histological biopsy grades: prospective analysis of 3 cohorts receiving methotrexate therapy for rheumatoid arthritis. , 1996, The Journal of rheumatology.

[12]  D. Stablein,et al.  Combination treatment of rheumatoid arthritis using azathioprine and methotrexate: a 48 week controlled clinical trial. , 1996, The Journal of rheumatology. Supplement.

[13]  A. Munakata,et al.  Absence of measles viral genomic sequence in intestinal tissues from Crohn's disease by nested polymerase chain reaction. , 1996, Gut.

[14]  D. Stablein,et al.  Comparison of azathioprine, methotrexate, and the combination of the two in the treatment of rheumatoid arthritis. A forty-eight-week controlled clinical trial with radiologic outcome assessment. , 1995, Arthritis and rheumatism.

[15]  M. Gerig,et al.  A controlled double blind study of azathioprine in the management of Crohn's disease. , 1995, Gut.

[16]  R. Sartor.  Current concepts of the etiology and pathogenesis of ulcerative colitis and Crohn's disease. , 1995, Gastroenterology clinics of North America.

[17]  Korelitz Bi,et al.  Methotrexate for Crohn's disease. , 1995 .

[18]  S. West,et al.  Usefulness of the American College of Rheumatology recommendations for liver biopsy in methotrexate-treated rheumatoid arthritis patients. , 1995, Arthritis and rheumatism.

[19]  T. Karttunen,et al.  A controlled study of bone mineral density in patients with inflammatory bowel disease. , 1995, Gut.

[20]  K. Freedberg,et al.  The cost-effectiveness of liver biopsy in rheumatoid arthritis patients treated with methotrexate. , 1995, Arthritis and rheumatism.

[21]  Loyd,et al.  Methotrexate for the treatment of Crohn's disease. The North American Crohn's Study Group Investigators. , 1995, The New England journal of medicine.

[22]  D. Jewell,et al.  A comparison of budesonide with prednisolone for active Crohn's disease. , 1994, The New England journal of medicine.

[23]  J. Kremer,et al.  Methotrexate for Rheumatoid Arthritis , 1994 .

[24]  P. Munkholm,et al.  Frequency of glucocorticoid resistance and dependency in Crohn's disease. , 1994, Gut.

[25]  P. Dale,et al.  Pancytopenia associated with low dose methotrexate therapy. A regional survey. , 1993, The Journal of rheumatology.

[26]  J. Markowitz,et al.  Long-term 6-mercaptopurine treatment in adolescents with Crohn's disease. , 1990, Gastroenterology.

[27]  A. Mackenzie,et al.  Outcome of first-trimester exposure to low-dose methotrexate in eight patients with rheumatic disease. , 1990, The American journal of medicine.

[28]  S. Meltzer,et al.  6-Mercaptopurine in the management of inflammatory bowel disease: short- and long-term toxicity. , 1989, Annals of internal medicine.

[29]  R. Kozarek,et al.  Methotrexate induces clinical and histologic remission in patients with refractory inflammatory bowel disease. , 1989, Annals of internal medicine.

[30]  M. Weinblatt,et al.  Efficacy of low-dose methotrexate in rheumatoid arthritis. , 1985, The New England journal of medicine.

[31]  K. Ewe,et al.  European cooperative Crohn's disease study (ECCDS) : Results of drug treatment , 1984 .

[32]  B. Pasternack,et al.  Treatment of Crohn's disease with 6-mercaptopurine. A long-term, randomized, double-blind study. , 1980, The New England journal of medicine.

[33]  R. Summers,et al.  National Cooperative Crohn's Disease Study: results of drug treatment. , 1979, Gastroenterology.

[34]  H. Mekhjian,et al.  National Cooperative Crohn's Disease Study: adverse reactions to study drugs. , 1979, Gastroenterology.

[35]  J. Lennard-jones,et al.  DOUBLE-BLIND WITHDRAWAL TRIAL OF AZATHIOPRINE AS MAINTENANCE TREATMENT FOR CROHN'S DISEASE , 1978, The Lancet.

[36]  F Kern,et al.  Development of a Crohn's disease activity index. National Cooperative Crohn's Disease Study. , 1976, Gastroenterology.

[37]  G. Greenberg,et al.  Oral budesonide as maintenance treatment for Crohn's disease: a placebo-controlled, dose-ranging study. Canadian Inflammatory Bowel Disease Study Group. , 1996, Gastroenterology.

[38]  N. Vakil,et al.  Steroid-related osteonecrosis in inflammatory bowel disease. , 1989, Gastroenterology.